Eric Lindquist: Why Did Pfizer License a Promising Cancer Drug to Celcuity?
In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Eric Lindquist, biotech entrepreneur and former Chief Business and Commercial Officer at Celcuity, about the 2021 deal to license gedatolisib from Pfizer.
Drawing on Lindquist’s experience with the transaction, they explore portfolio fit, the responsibilities of advancing a medicine, and how funding, pricing policy, and international competition shape drug development and patient access.
Key Topics:
Drug Licensing: The Pfizer-Celcuity agreement, portfolio fit, development responsibilities.
Pricing Policy…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.